Skip to content
Menu

Cingulate Inc. CINGW

Full chart Compare
Set alert

Price alert · CINGW

All alert types
0.00 USD 0.00 (-2.70%)

Regular-session close

0.00 0.00 -16.67%

After hours · Nov 19, 7:57 PM ET

0.0036 Day range 0.0036
0.0036 52-week range 0.0036
YTD
-5.26%
1 year
-5.26%

 

No chart data for this range yet.
Market cap
25.66K
EPS (ttm)
-1.73
YTD return
-5.26%
1-year return
-5.26%
Price / book
0.01
Volume
10.18K
Open
0.0385
Previous close
0.0037
Day's range
0.0036 – 0.0036
52-week range
0.0036 – 0.0036

Key statistics

Free cash flow
-10.79M
Total cash
10.04M
Total debt
234.17K
Return on equity
-273.82%

About Cingulate Inc.

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on CINGW — it syncs with the Stock Master app.

Institution ownership

CINGW institution ownership
Holder% heldSharesValueReported
Altium Capital Management, LP7.56%270,00016.20KSep 29, 2024
Hudson Bay Capital Management Lp5.90%210,79812.65KSep 29, 2024
Citadel Advisors Llc0.55%19,4791.17KSep 29, 2024
UBS Group AG0.34%12,297737Sep 29, 2024
Virtu Financial LLC0.31%11,159669Sep 29, 2024
GoalVest Advisory, LLC0.08%3,000179Sep 29, 2024